Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy
Top Cited Papers
- 11 December 2014
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 371 (24), 2277-2287
- https://doi.org/10.1056/nejmoa1409354
Abstract
Idiopathic membranous nephropathy is an autoimmune disease. In approximately 70% of patients, it is associated with autoantibodies against the phospholipase A2 receptor 1 (PLA2R1). Antigenic targets in the remaining patients are unknown. Using Western blotting, we screened serum samples from patients with idiopathic membranous nephropathy, patients with other glomerular diseases, and healthy controls for antibodies against human native glomerular proteins. We partially purified a putative new antigen, identified this protein by means of mass spectrometry of digested peptides, and validated the results by analysis of recombinant protein expression, immunoprecipitation, and immunohistochemical analysis. Serum samples from 6 of 44 patients in a European cohort and 9 of 110 patients in a Boston cohort with anti-PLA2R1–negative idiopathic membranous nephropathy recognized a glomerular protein that was 250 kD in size. None of the serum samples from the 74 patients with idiopathic membranous nephropathy who were seropositive for anti-PLA2R1 antibodies, from the 76 patients with other glomerular diseases, and from the 44 healthy controls reacted against this antigen. Although this newly identified antigen is clearly different from PLA2R1, it shares some biochemical features, such as N-glycosylation, membranous location, and reactivity with serum only under nonreducing conditions. Mass spectrometry identified this antigen as thrombospondin type-1 domain-containing 7A (THSD7A). All reactive serum samples recognized recombinant THSD7A and immunoprecipitated THSD7A from glomerular lysates. Moreover, immunohistochemical analyses of biopsy samples from patients revealed localization of THSD7A to podocytes, and IgG eluted from one of these samples was specific for THSD7A. In our cohort, 15 of 154 patients with idiopathic membranous nephropathy had circulating autoantibodies to THSD7A but not to PLA2R1, a finding that suggests a distinct subgroup of patients with this condition. (Funded by the French National Center for Scientific Research and others.)Keywords
This publication has 20 references indexed in Scilit:
- Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patientsNephrology Dialysis Transplantation, 2014
- Journal of the American Society of Nephrology, 2014
- Defining cell-type specificity at the transcriptional level in human diseaseGenome Research, 2013
- Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathyClinica Chimica Acta; International Journal of Clinical Chemistry, 2013
- Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsiesLaboratory Investigation, 2013
- Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathyNephrology Dialysis Transplantation, 2012
- Antiphospholipase A2 Receptor Antibody Titer and Subclass in Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2012
- Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathyKidney International, 2012
- Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2011
- An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritisNephrology Dialysis Transplantation, 2011